Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc.

Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ — The National Cancer Center (Tokyo, Japan) and The University of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a…